: Pharmacokinetics of Enoxaparin After Coronary Artery Bypass Graft Surgery
Venous Thromboembolism, Pulmonary Embolism, Thromboprophylaxis
About this trial
This is an interventional prevention trial for Venous Thromboembolism focused on measuring Venous thromboembolism, pulmonary embolism, thromboprophylaxis, anticoagulant, anti-FXa, low-molecular weight heparin, enoxaparin
Eligibility Criteria
Inclusion Criteria:
- BMI between 18-33 kg/m2
- Elective on-pump CABG operation
- Indication for post-operative pharmacological thromboprophylaxis
- Written informed consent obtained from the patient or his/her legal representative.
Exclusion Criteria:
- Other indications for anticoagulant therapy than thromboprophylaxis
- Known heparin induced thrombocytopenia (HIT), or hypersensitivity to enoxaparin or heparin
- Any long-term anticoagulant medication, expect low-dose aspirin
- Major bleeding within the last week unless definitively treated
- Blood platelet count <20, P-TT <20 % or INR >1.7
- GFR less than 30 ml/min/1.73 m2 estimated from serum creatinine by applying Cockcroft-Gault equation 13 or chronic dialysis
- Known HIV, HBV, or HCV infection
- Pregnancy
Sites / Locations
- Tampere University Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Active Comparator
Active Comparator
Active Comparator
Active Comparator
Enoxaparin 40 mg s.c.
Enoxaparin 40 mg i.v.
Enoxaparin 0.5 mg/kg s.c.
Enoxaparin 1 mg/kg i.v.
Subcutaneous enoxaparin (Klexane®, Sanofi-Aventis) 40 mg thromboprophylaxis every 24 hours for three days (72 hours)
Enoxaparin thromboprophylaxis (40 mg) daily as continuous intravenous infusion for three days (72 hours)
Subcutaneous enoxaparin (Klexane®, Sanofi-Aventis) 0.5 mg/kg thromboprophylaxis twice a day for three days (72 hours)
Enoxaparin thromboprophylaxis 1 mg/kg daily as continuous intravenous infusion for three days (72 hours)